Furthermore, compared with the AF + rivaroxaban group, the expressions of inflammatory biomarkers (TNF-α, IL-1β, IL-6, and IL-10) in the AF + edoxaban group were downregulated (p < 0.05), which presented that edoxaban was superior to rivaroxaban in the aspect of reducing the inflammation in the AF mice (Figure 5B). The gene discussed is IL6; the disease is atrial fibrillation.